SGLT2i effect on atrial fibrillation: A network meta-analysis of randomized controlled trials.

Dapagliflozin use was associated with significant reduction in AF risk as compared to placebo in overall population and patients with diabetes, whereas the use of other gliflozins did not significantly reduce AF occurrence.